Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evogene (EVGN)
NASDAQ:EVGN
Holding EVGN?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.73Last Year’s EPS
-$1.3Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 21, 2024
|% Change Since: 0.00%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of positive developments, such as growth in revenue over the first nine months, strategic collaborations, and product expansions. However, these were countered by a decrease in Q3 revenues, increased operating losses, and delays in seed deliveries. The sentiment is balanced with promising future prospects but immediate challenges in financial performance.Company Guidance
During the Q3 2024 earnings call for Evogene, the company provided guidance for continued revenue growth in the full year of 2024, primarily driven by Casterra's supply of existing seed orders. The company's revenue for the first nine months of 2024 was approximately $6.9 million, an increase from $5.1 million in the same period of 2023. However, Q3 2024 revenue was approximately $1.8 million, a decrease from $3.8 million in Q3 2023, due to a $2.5 million license fee payment received by Lavie Bio in the previous year. Evogene's projected cash usage for 2024, excluding Biomica and Lavie Bio, is estimated at $8 million to $10 million, a decrease from $12.5 million in 2023. Additionally, Evogene is focusing on strengthening its cash position by reducing expenses, including a 16% reduction in headcount, and exploring business opportunities to inject funds into the company and its subsidiaries.Revenue Growth in First 9 Months of 2024
Total revenues reached approximately $6.9 million, up from $5.1 million in the first 9 months of 2023.
Collaboration with Google Cloud
Evogene announced a collaboration with Google Cloud to develop a generative AI model for novel small molecule design, increasing the training set from 6 million to 40 billion molecules.
Casterra's Seed Production Milestone
Casterra completed seed production infrastructure in Kenya and Brazil, with significant shipments initiated.
Lavie Bio's Product Expansion
Lavie Bio expanded its product Yalos to winter wheat and soybean, expecting initial sales in spring 2025.
AgPlenus Fungicide Program
AgPlenus initiated a new fungicide program focusing on Septoria, with promising targets identified.
Biomica's Positive Clinical Study Results
Biomica's Phase I clinical study for BMC128 showed positive responses in 5 patients.
---
EVGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EVGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 21, 2024 | $1.65 | $1.60 | -3.03% |
| Aug 22, 2024 | $3.98 | $3.55 | -10.80% |
| May 23, 2024 | $7.40 | $7.20 | -2.70% |
| Mar 07, 2024 | $9.29 | $9.60 | +3.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Evogene (EVGN) report earnings?
Evogene (EVGN) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Evogene (EVGN) earnings time?
Evogene (EVGN) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVGN EPS forecast?
EVGN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.73.
---